A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bo
A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Zoledronic acid anhydrous
What it measured
Main measures
The hypothesis is that a single zoledronate infusion prior to a course of corticosteroid will prevent the rapid increase in bone resorption which normally occurs in response to high dose steroid therapy. The primary outcome will be a significant difference in serum CTX according to treatment group at day 7 the study.
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: Age 18-65 with established MS Exclusion: Previous diagnosis of osteoporosis
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Patients with MS who are experiencing an exacerbation of their disease symptoms are traditionally treated with either a 3 day course of intravenous high dose corticosteroids (methylprednisolone) or sometimes a 5 day course of oral corticosteroids (methylprednisolone).The principal objective is to discover whether giving a single intravenous infusion of a bisphosphonate, zoledronate, immediately prior to the corticosteroid therapy will prevent the bone thinning effect of the steroid and the associated increase in fracture risk.
Loading reviews and guidelines…
History
Started
Dec 2008